In a phase 3, open-label safety extension study, researchers evaluated the safety of oral edaravone in patients with amyotrophic lateral sclerosis over 96 weeks.

New drug delivery technologies, such as nanoparticles, hydrogels, and self-powered microgrippers, are showing great potential ...

Hello and welcome to Virtual Investor Conferences. On behalf of the Life Sciences Investor Forum and our co-host, Zacks Small Cap Research, we're very pleased you joined us for our quarterly ...

The global injectable drug delivery devices market size was estimated at USD 519 billion in 2024 and is predicted to reach ...

Pakistan: A recent systematic review and meta-analysis comparing the oral and vaginal administration of misoprostol for ...

The growing prevalence of diabetes, primarily due to obesity, aging populations, and sedentary lifestyles, is a key factor ...

The Company anticipates filing its NDA for GTx-104 in the second quarter of 2025. Acceptance of the NDA will be subject to the FDA’s review of the complete filing.

About Bio-Convert Bio-Convert’s mission is to develop the preferred treatment for oral leukoplakia. Our innovative therapeutic agent, QR-02, uses a novel drug delivery technology, that enables more ...

(Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

The race is on to make the first oral weight loss medicines, but smaller US pharmacies may have already got there – if they ...

But while most of the (admittedly small) research centers around using topical minoxidil for nail growth, it’s “feasible” ...